image

14.3. The prognostic value of HLC analysis at baseline

Chapter 14

Hevylite assays allow the measurement of isotype-specific suppression of the uninvolved HLC-pair (i.e. suppression of IgGλ in an IgGκ patient) (Section 11.2). As HLC-pair suppression has been identified as an adverse prognostic marker in MM and MGUS patients (Chapters 13 and 20), it may also have prognostic significance in SMM. In the largest prospective study of HLC and SMM published to date, HLC-pair suppression was observed in 39/50 (78%) patients at diagnosis, compared with 32/50 (64%) patients who had conventional immunoparesis, i.e. suppression of uninvolved polyclonal immunoglobulins [308]. Of the 18 patients without immunoparesis, HLC-pair suppression was present in 8/18 cases and was associated with adverse biological features such as more skewed κ/λ sFLC ratios and a more pronounced distribution of abnormal/normal plasma cells.

In an initial investigation by Maisnar et al. [309], HLC-pair suppression was associated with increased risk of progression in IgG (n=51, p=0.006) but not IgA (n=20) SMM, although patient numbers were small. Further studies are now required to confirm the prognostic significance of HLC-pair suppression in SMM.

References

    • 1. Costello R, Espana K, Korde N, Kwok M, Zingone A, Yancey MA et al. Hevylite assays detect a hidden immunoparesis associated with adverse biology in myeloma precursor disease: A prospective clinical study. Blood 2011;118:5065a
    • 2. Maisnar V, Pour L, Pika T, Straub J, Walterova L, Gregora E et al. The importance of immunoparesis assessment in patients with asymptomatic multiple myeloma - first results of a new CMG project. Hematology Reports 2015;7:C58a